Campbell & Co Investment Adviser’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Campbell & Co Investment Adviser’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-50,735	Closed	-$818K	–	1424
2023 Q4	$818K	Buy	+50,735	New	+$647K	0.07%	475
2023 Q2	–	Sell	-42,881	Closed	-$663K	–	1178
2023 Q1	$663K	Buy	42,881 +14,664	+52%	+$245K	0.12%	305
2022 Q4	$462K	Buy	+28,217	New	+$459K	0.11%	348

Other funds holding DCPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Campbell & Co Investment Adviser's DCPH Position: Q1 2024 in Review

Campbell & Co Investment Adviser sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2024, closing a stake of 50,735 shares — an estimated $818K sold.

Campbell & Co Investment Adviser first reported a position in DCPH in Q4 2022 and held it in 3 quarters. The position peaked at $818K in Q4 2023. 177 funds tracked by Wall St. Rank hold DCPH as of Q1 2024.

Campbell & Co Investment Adviser reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Campbell & Co Investment Adviser sold 50,735 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $818K.
Campbell & Co Investment Adviser first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
Campbell & Co Investment Adviser's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $818K in Q4 2023.
177 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2024, filed 10 May 2024.